Online first
Artykuł przeglądowy
Opublikowany online: 2023-07-11
Wyświetlenia strony
764
Wyświetlenia/pobrania artykułu
50
Tebentafusp w leczeniu zaawansowanego czerniaka gałki ocznej
Streszczenie
Tebentafusp jest wskazany do stosowania w monoterapii w leczeniu nieresekcyjnego lub przerzutowego czerniaka błony naczyniowej oka u dorosłych chorych, u których występuje ludzki antygen leukocytarny (HLA)-A*02:01. Tebentafusp jest bispecyficznym przeciwciałem zwiększającym interakcje między limfocytami T a komórkami czerniaka, przez co wykazuje aktywność przeciwnowotworową. W badaniu III fazy tebentafusp wydłużył czas przeżycia całkowitego w porównaniu z leczeniem wybranym przez badaczy. Tebentafusp jest pierwszym lekiem zarejestrowanym w wymienionym wskazaniu.
Słowa kluczowe: czerniak gałki ocznejtebentafuspimmunoterapia
Referencje
- Charakterystyka produktu leczniczego Kimmtrak (tebentafusp). https://www.ema.europa.eu/en/documents/product-information/kimmtrak-epar-product-information_pl.pdf.
- Oates J, Hassan NJ, Jakobsen BK. ImmTACs for targeted cancer therapy: Why, what, how, and which. Mol Immunol. 2015; 67(2 Pt A): 67–74.
- Boudousquie C, Bossi G, Hurst JM, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8 and CD4 T cells. Immunology. 2017; 152(3): 425–438.
- Wagner SN, Wagner C, Schultewolter T, et al. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. Cancer Immunol Immunother. 1997; 44(4): 239–247.
- de Vries TJ, Trancikova D, Ruiter DJ, et al. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer. 1998; 78(9): 1156–1161.
- Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008; 35(5): 433–444.
- Skipper JC, Gulden PH, Hendrickson RC, et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer. 1999; 82(5): 669–677, doi: 10.1002/(sici)1097-0215(19990827)82:5<669::aid-ijc9>3.0.co;2-#.
- Marincola FM, Shamamian P, Rivoltini L, et al. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol. 1994; 16(1): 13–23.
- Damato BE, Dukes J, Goodall H, et al. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel). 2019; 11(7).
- Harper J, Adams KJ, Bossi G, et al. An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLoS One. 2018; 13(10): e0205491.
- Liddy N, Bossi G, Adams KJ, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012; 18(6): 980–987.
- Middleton M, Steven N, Evans T, et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma. Journal of Clinical Oncology. 2016; 34(15_suppl): 3016–3016.
- Carvajal RD, Nathan P, Sacco JJ, et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J Clin Oncol. 2022; 40(17): 1939–1948.
- Sacco J, Carvajal R, Butler M, et al. 538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. Journal for ImmunoTherapy of Cancer. 2021; 9(Suppl 2): A568–A568.
- Sacco JJ, Carvajal R, Butler MO, et al. 64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology. 2020; 31: S1442–S1443.
- Nathan P, Hassel JC, Rutkowski P, et al. IMCgp100-202 Investigators. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021; 385(13): 1196–1206.
- Sullivan R, Milhem M, Demidov L, et al. Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM). Journal of Clinical Oncology. 2022; 40(16_suppl): 9585–9585.
- Leach E, Stanhope S, Naidoo R, et al. 868 Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels. Journal for ImmunoTherapy of Cancer. 2021; 9(Suppl 2): A909–A909.
- Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the spanish multidisciplinary melanoma group (GEM-1402). J Clin Oncol. 2021; 39(6): 586–598.
- Bol KF, Ellebaek E, Hoejberg L, et al. Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma. Cancers (Basel). 2019; 11(10).
- Roviello G, Andre F, Venturini S, et al. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. Eur J Cancer. 2017; 86: 257–265.
